Bayer, Preps

Bayer Preps US Rollout of Sunharbo as Deutsche Bank Lifts Target to EUR 65

Published on 11/17/2026 at 11:31 | Editorial boerse-global.de
Bayer will ship its newly FDA-approved stroke medicine SUNHARBO in the US from mid-to-late November, as Deutsche Bank lifts its price target to EUR 65.
Bayer, Preps, Rollout, Sunharbo, Bank, Lifts, Target, EUR, FDA-approved, SUNHARBO Illustration mit AI erstellt.

Bayer is gearing up to ship its newly approved stroke medicine SUNHARBO in the United States from mid-to-late November, following last week's green light from the Food and Drug Administration. The active ingredient, asundexian, won clearance for adults who have recently suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, with the drug designed to cut the risk of further strokes.

The approved regimen is a 50 mg dose given alongside antiplatelet therapy. The filing rested on the Phase 3 OCEANIC-STROKE trial. Bayer has billed asundexian as the world's first approved factor XIa inhibitor, positioning the drug around reducing the risk of secondary strokes.

A Second Approval, This Time in China

The US decision was not the company's only regulatory win of late. At the start of November, China cleared sevabertinib as a first-line treatment for patients with HER2-mutated non-small cell lung cancer — a separate product aimed at a different patient population from the asundexian label.

Should investors sell immediately? Or is it worth buying Bayer?

Third-Quarter Figures and a Brighter Outlook

Those approvals landed alongside third-quarter 2026 results, published in early November, which showed group revenue of EUR 10.1 billion and EBITDA before special items of EUR 1.62 billion. Bayer also raised part of its full-year guidance, lifting its forecast for EBITDA before special items to a range of EUR 9.8 billion to EUR 10.3 billion. The revision did not extend across the entire outlook.

Deutsche Bank Raises Its Sights

Deutsche Bank Research responded by hoisting its price target to EUR 65 from EUR 60 last week, keeping its buy rating intact. Analyst Virginie Boucher-Ferte marked up her EBITDA and earnings-per-share estimates for 2027 and 2028 in the wake of the quarterly update.

Roundup Litigation Back in Focus

On the legal front, a US federal judge reportedly examined yesterday which Roundup claims can proceed following a Supreme Court ruling. The review concerns the litigation surrounding Monsanto's glyphosate-based herbicide, turning attention to how individual cases move forward after the court's decision.

Bayer shares slipped 0.7% today, a pullback that follows a positive session on Monday. The company and analyst news that underpinned that earlier advance had all been published in the preceding weeks.

Ad

Bayer Stock: New Analysis - 17 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYER | boerse | 70526092 |